S. Hoshide

Safety and Pharmacokinetics of Urtoxazumab, a Humanized Monoclonal Antibody, against Shiga-Like Toxin 2 in Healthy Adults and in Pediatric Patients Infected with Shiga-Like Toxin-Producing Escherichia coli

R. Santoro, D. Allende, E. López, 2009, Antimicrobial Agents and Chemotherapy.

Pharmacokinetics and Pharmacodynamics of Febuxostat (TMX‐67), a Non‐Purine Selective Inhibitor of Xanthine Oxidase/Xanthine Dehydrogenase (NPSIXO) in Patients with Gout and/or Hyperuricemia

H. Yamanaka, N. Kamatani, K. Takeda, 2004, Nucleosides, nucleotides & nucleic acids.

An Epidemiologic Surveillance of Shiga-like Toxin-producing Escherichia coli Infection in Argentinean Children: Risk Factors and Serum Shiga-like Toxin 2 Values

Y. Katsuura, R. Santoro, E. López, 2012, The Pediatric infectious disease journal.

In vitro drug–drug interaction studies with febuxostat, a novel non-purine selective inhibitor of xanthine oxidase: plasma protein binding, identification of metabolic enzymes and cytochrome P450 inhibition

S. Nishimura, M. Kanou, K. Taniguchi, 2008 .

PK/PD and Safety of a Single Dose of TMX‐67 (Febuxostat) in Subjects with Mild and Moderate Renal Impairment

T. Hosoya, I. Ohno, K. Komoriya, 2004, Nucleosides, nucleotides & nucleic acids.

Species specificity of anticoagulant activity of activated human protein C: involvement of factor V as well as protein S.

Y. Katsuura, T. Nakagaki, S. Miyamoto, 1996, Thrombosis research.

NUCLEOSIDES, NUCLEOTIDES & NUCLEIC ACIDS

K. Komoriya, M. Tsuchimoto, T. Ishikawa, 2004 .